Gilead Sciences Inc (GILD)
111.44
-1.91
(-1.68%)
USD |
NASDAQ |
Mar 14, 16:00
111.50
+0.06
(+0.05%)
After-Hours: 20:00
Key Stats
Price and Performance | |
---|---|
Market Cap | 138.78B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 55.74% |
Valuation | |
PE Ratio | 301.19 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 4.875 |
Price to Book Value | 7.180 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 0.79 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 1.382 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 38.10% |
Profile
Edit
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
URL | https://www.gilead.com |
Investor Relations URL | https://investors.gilead.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | Apr. 24, 2025 |
Last Earnings Release | Feb. 11, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 14, 2025 |
Ratings
Profile
Edit
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
URL | https://www.gilead.com |
Investor Relations URL | https://investors.gilead.com/ |
HQ State/Province | California |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | Apr. 24, 2025 |
Last Earnings Release | Feb. 11, 2025 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Mar. 14, 2025 |